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Abstract
Background: To investigate the feasibility of gene therapy in treating Epstein-Barr virus (EBV)-
associated cancer by employing the suicide gene, herpes simplex virus thymidine kinase/ganciclovir
(HSV-tk/GCV), which uses the signaling pathway through the HIV-long terminal repeat (LTR) gene
which is expressed from a nuclear factor-κB (NF-κB)-binding motif-containing promoter that is
regulated by EBV-latent membrane protein 1 (LMP1) via NF-κB.
Methods: First, we constructed the plasmid pVLTR-tk, which was regulated by EBV-LMP1 via NF-
κB, and then investigated the cytotoxic effect of the pVLTR-tk/GCV on cancer cells, using MTT
assays, clonogenic assays, flow cytometry, and animal experiments.
Results: The activation of TK was increased after transfection of the pVLTR-tk into the EBV-LMP1
positive cells. After GCV treatment, the clonogenicity and survival of the cells substantially
declined, and a bystander effect was also observed. The LMP1 positive cells exhibited remarkable
apoptosis following pVLTR-tk/GCV treatment, and the pVLTR-tk/GCV restrained tumor growth
in vivo for EBV-LMP1 positive cancers.
Conclusion: The pVLTR-tk/GCV suicide gene system may be used as a new gene targeting
strategy for EBV-associated cancer.
Background
The Epstein-Barr virus (EBV) has been implicated in the
pathogenesis of several human malignant tumors includ-
ing nasopharyngeal carcinoma (NPC), Hodgkin's disease,
and Burkitt's lymphoma [1]. EBV-encoded latent mem-
brane protein 1 (LMP1), which is considered an oncopro-
tein, plays an important role in the progress of
carcinogenesis via regulation of transformation, prolifera-
tion, apoptosis, and other biological processes of the cell
[2]. EBV-LMP1 has also been found to regulate the devel-
opment and progression of tumors via activated nuclear
factor-κB (NF-κB) [3]. Our research has previously
showed that EBV-LMP1 continuously activates NF-κB by
directly combining tumor necrosis factor receptor-acti-
vated factor (TRAF) with the C-terminal activating regions
1 and 2 (CTAR1 and CTAR2) of LMP1 [4-6].
The long terminal repeat (LTR) of HIV is located at both
the N-terminal and C-terminal domains of the HIV
genome. Many cis-acting elements are associated with the
expression of charge of the HIV gene in the LTR, including
two NF-κB motifs. Several studies have indicated that
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LMP1 possesses the ability to transactivate HIV-LTR
through the NF-κB binding motifs [7-9].
The herpes simplex virus-thymidine kinase (HSV-tk) gene
has been used in the treatment of many different types of
tumors in clinical trials [10,11]. Research has showed that
HSV-tk/GCV exhibits not only direct cytotoxicity but also
a bystander effect (BSE), which builds up effectively the
function of killing and wounding of the HSV-tk/GCV sys-
tem [12,13]. However, one of the major limitations of
gene therapy using HSV-tk/GCV is the effective expression
of therapeutic genes in target cells.
In this study, we examined the feasibility of using the sig-
naling pathway of LMP1, which stimulates HIV-LTR via
the two NF-κB binding sites, as a therapeutic strategy for
the treatment of EBV-associated cancer. Because LMP1 is
expressed only in tumor cells (and not in normal tissue
cells), this therapeutic strategy could enhance the tumor-
specific targeting capacity of HSV-tk/GCV for EBV-associ-
ated cancer.
Methods
Cells
CNE1: The LMP1 negative high differentiated nasopha-
ryngeal squamous carcinoma cell line; CNE1-LMP1: sta-
ble LMP1 integrated nasopharyngeal squamous
carcinoma cell line; HNE2-LMP1: lowly differentiated and
stable LMP1 integrated nasopharyngeal squamous carci-
noma cell line [14,15]; Raji (ATCC CCL 86): Burkitt's lym-
phoma cell line, LMP1 positive cell; and B95-8(ATCC CRL
1612): B lymphocyte cell line transformed by the EBV.
Cells were cultured in RPMI 1640 medium (GIBCO) sup-
plemented with 10% fetal bovine serum.
Plasmids
The HSV-TK fragment from the HSV-TK gene-containing
plasmid, pAB109, was excised by BglII/PvuII, and sub-
cloned into the pGN-LTR vector (the LacZ reporter plas-
mid regulated by HIV-LTR, Dr. Chang YS, Chang-Gung
University) at the EcoRI/SmaI site (with LacZ removed).
This is the expression plasmid that contains HSV-tk regu-
lated by HIV-LTR. The plasmid constructs were verified by
sequence analysis.
Assay of TK activity
Forty-eight hours after NPC cells (CNE1, CNE1-LMP1,
HNE2-LMP1) were transiently transfected using the
SuperFect™ transfection reagent (QIAGEN) with pVLTR-
tk, cultures were harvested and lysed with lysis buffer (50
mM Tris-HCl, 1 mM EDTA, 20 g/L sodium dodecyl sulfate
(SDS), 5 mM DTT, and 10 mM phenylmethylsulfonyl flu-
oride). Following centrifugation, 20 μL of supernatant
was mixed with 100 μL of TK reaction buffer (125 mM
Tris-HCl, pH 7.8; 2 mM MgCl2; 200 mM KCl; 100 mM
NH4Cl; 4 mM mercaptoethanol; 2 mM ATP; 0.5 mg/mL
fetal bovine serum; and 3 × 10-7M  3H thymidine), and
incubated at 37°C for 30 min. After incubation, 50 μL of
the reaction mixture was spotted onto a piece of 1 cm2
Whatman DE-81 filter paper. The filters were washed
three times with 95% ethanol, transferred to 5 mL of scin-
tillation buffer after drying, and counted using the Beck-
man LS 5000 TD multipurpose scintillation counter
(Beckman Instruments). The efficiency of transfection
proofread by co-transfection of pRSVβ-gal Reporter Sys-
tem (Promega).
Cell proliferation assay
Cells were plated at a density of 2 × 104 cells/well in 48-
well plates 24 hours before transfection with the pVLTR-tk
using the SuperFect™ transfection reagent. Following the
24-hours incubation period, cells were cultured for 48
hours in the presence of different concentrations (50 μg/
mL, 100 μg/mL, 200 μg/mL, 300 μg/mL, 500 μg/mL) of
GCV. At the end of the culture period, 40 μL of MTT (5
mg/mL) was added to each well. After 4 hours of incuba-
tion with MTT, DMSO (200 μL/well) was added. The OD
value of each well was read using a microplate reader (ELX
800; Bio-tek Instruments) at 570 nm. The survival rate of
cells was expressed as A/B 100%, where A was the absorb-
ance value from the experimental cells and B was that
from the control cells, which were not treated with GCV.
Bystander effect analysis
Twenty-four hours after tumor cells were transfected with
the pVLTR-tk/GCV, different proportions (0%, 10%, 50%,
90%, and 100%), respectively, of transfected and untrans-
fected cells that had been adjusted to a density of 2 × 104
cells/well were cocultured in 48-well plates at 37°C for 48
hours in the presence of 200 μg/mL of GCV. The
bystander effect was determined using the MTT method,
as described previously.
Clonogenic assay
Cells (5 × 102 cells/well) were transfected with the pVLTR-
tk in the presence of 200 μg/mL of GCV. When the resist-
ant colonies were an appropriate size following incuba-
tion, the plates were fixed in 10% methanol and 5% acetic
acid for 10 min. After the plates were stained in 0.1% crys-
tal violet/20% ethanol for 5 min, the colonies were
counted.
Detection of apoptosis by flow cytometry
Forty-eight hours after transfection of the pVLTR-tk using
the SuperFect™ transfection reagent into 1 × 106 cells and
treatment with 200 μg/mL of GCV, both adherent and
floating cells were harvested by trypsinization. The cells
were centrifuged, and the cell pellets were washed with
phosphate-buffered saline (PBS). The cells were fixed in
70% ethanol overnight. They were then washed and resus-Journal of Experimental & Clinical Cancer Research 2008, 27:42 http://www.jeccr.com/content/27/1/42
Page 3 of 7
(page number not for citation purposes)
pended in Hank's buffered saline solution, and incubated
in phosphate-citric acid buffer for 5 min. Following the 5-
min incubation period, the cells were centrifuged, and the
pellet was resuspended in Hank's buffered saline solution
containing propidium iodide (10 μg/mL) and RNase (100
μg/mL). Following the 30-min incubation period at room
temperature, the cells were quantified with a FACScan
(Becton Dickinson) flow cytometer, using 488- and 630-
nm filters for excitation and emission, respectively. The
salmon sperm DNA (ssDNA) used as a DNA toxicity con-
trol.
Animal experiment
Twenty-four hours after transfection with pVLTR-tk using
SuperFect™ transfection reagent, 5 × 106  cancer cells
(CNE1, CNE1-LMP1) in 0.2 mL of serum-free RPMI 1640
medium were inoculated s.c. into the right flank of 8- to
12-week-old male BALB/c nude mice (4-5 mice for each
treatment group). The cancer growth was monitored every
2 days using calipers. When tumors reached a mean tumor
diameter of 4 to 5 mm, GCV (100 μmg/g avoirdupois)
was injected directly into the tumor every 24 hours for 7
days. Following a few days of observation, the mice were
sacrificed by cervical dislocation, tumors were removed
and frozen rapidly, and 5.0-μm cryosections were pre-
pared for histopathological studies.
Histopathological examination
The cryosections from the treated tumor tissues were
stained with hematoxylin and eosin, and analyzed by
light microscopy.
Statistical analysis
All the data were analyzed using the Student's t test. The
statistical difference P < 0.05 was considered significant.
Results
EBV-LMP1 promote the TK activity of the pVLTR-tk
As shown in Figure 1, the TK enzymatic activity of CNE1
cells transfected with the pVLTR-tk was similar to that of
untransfected cells, with the cpm volume being about 1 ×
105, indicating that the expression of the endogenous tk
gene was at a low level. However, unlike the untransfected
cells, the TK enzymatic activity in CNE1-LMP1 and HNE2-
LMP1 cells transfected with the pVLTR-tk maintained high
levels-about three times higher than that in CNE1 cells (P
< 0.01)-indicating that high expression of the pVLTR-tk
gene is regulated by EBV-LMP1.
Inhibition of LMP1 positive cells growth with pVLTR-tk/
GCV
CNE1, CNE1-LMP1, HNE2-LMP1, B95-8, and Raji cells
were transfected with the pVLTR-tk, and incubated with
GCV at various concentrations. A decrease in cell viability
was observed upon increasing GCV concentration, the
highest toxicity being obtained at 500 μg/mL of GCV for
all cell lines. These results suggested that for GCV concen-
trations higher than 500 μg/mL, the limiting factor affect-
ing cytotoxicity is not related to the level of thymidine
kinase expression. As illustrated in Figure 2, in CNE1-
LMP1, HNE2-LMP1, B95-8, and Raji cells, the survival cell
rates were about 80% with 50 μg/mL of GCV, about 40%
with 100 μg/mL and 200 μg/mL of GCV, and about 20%
with 300 μg/mL of GCV. When the effects at the same con-
centration of GCV are compared, these cells seem to be
Thymidine kinase (tk) activity assay Figure 1
Thymidine kinase (tk) activity assay. Tk activity of 
CNE1, CNE1-LMP1, and HNE2-LMP1 cells after transfection 
with pVLTR-tk.
pVLTR-tk/GCV inhibit the cell proliferation in LMP1 positive  cells Figure 2
pVLTR-tk/GCV inhibit the cell proliferation in LMP1 
positive cells. Cells were transfected with pVLTR-tk and 
treated with GCV. Cell proliferation was measured by MTT 
analysis.Journal of Experimental & Clinical Cancer Research 2008, 27:42 http://www.jeccr.com/content/27/1/42
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more sensitive to GCV than CNE1 cells. (The level of tox-
icity remained unchanged in CNE1 cells at 50 to 300 μg/
mL of GCV.) These results indicated that transfection with
the pVLTR-tk increases sensitivity to GCV in EBV-LMP1
positive cells.
A bystander effect was found in the presence of pVLTR-tk/
GCV
As shown in Figure 3, 50% of these transfectants could kill
60% of the cocultured cells, and 10% of these transfect-
ants could kill 40% of the cocultured cells, which is indic-
ative of a marked bystander effect. However, the most
prominent bystander effect was found in the presence of
the pVLTR-tk.
pVLTR-tk/GCV inhibit survival of the LMP1 positive cells
As shown in Figure 4, the average cell survival rate of
CNE1 cells treated with GCV (77.4%) was higher than
that of CNE1 cells transfected with pVLTR-tk and treated
A bystander effect was found in the presence of pVLTR-tk Figure 3
A bystander effect was found in the presence of 
pVLTR-tk.
pVLTR-tk/GCV restrain cell survival in LMP1 positive cells Figure 4
pVLTR-tk/GCV restrain cell survival in LMP1 positive cells. Cells were transfected with pVLTR-tk and treated with 
GCV. Cell survival was measured by a Clonogenic assay.Journal of Experimental & Clinical Cancer Research 2008, 27:42 http://www.jeccr.com/content/27/1/42
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with GCV (37.6%). The difference in the average cell sur-
vival rate between CNE1-LMP1 cells treated with GCV
(72.8%) and that of CNE1-LMP1 cells transfected with
pVLTR-tk and treated with GCV (0.5%, P < 0.001) was
even more pronounced. The results indicated that EBV-
LMP1 positive cells are more sensitive to pVLTR-tk/GCV
in clonogenic assays.
Induce the apoptosis in LMP1 positive cells with pVLTR-tk/
GCV
The percentage of cell apoptosis in HNE2-LMP1 and
CNE1-LMP1 cells was about 20% following treatment
with the pVLTR-tk/GCV. A slightly higher percentage of
apoptosis occurred in CNE1 cells (7.8%, P < 0.01) com-
pared with that of CNE1 cells transfected with ssDNA/
GCV (1.4%) (Figure 5). The results indicated that treat-
ment of EBV-LMP1 positive cells with pVLTR-tk/GCV
induces cell apoptosis.
pVLTR-tk/GCV restrain the tumor growth
As shown in Figure 6, treatment with the pVLTR-tk/GCV
significantly suppressed the growth of EBV-LMP1 s.c.
tumors when compared with that of CNE1 cells (P  <
0.01), although EBV-LMP1 negative CNE1 s.c. tumors
also exhibited a moderate restrain effect after treatment
with pVLTR-tk/GCV. These results suggested that the
pVLTR-tk/GCV has a favorable antitumor effect in vivo.
EBV-LMP1 is capable of enhancing the cytotoxic effect of 
pVLTR-tk/GCV
Hematoxylin and eosin staining showed that the tumor
status of the CNE1+TK group and that of the CNE1-
LMP1+TK group were concordant with the pathology of
the tissue. In the CNE1+TK+GCV group, there were some
putrescence cells, whereas in the CNE1-LMP1+TK+GCV
group, there were a great number of putrescence cells.
Therefore, EBV-LMP1 is capable of enhancing the cyto-
toxic effect of pVLTR-tk/GCV (Figure 7).
Discussion
HSV-tk/GCV systems have been shown to induce effec-
tively the killing and wounding of many malignant
tumors [16,17]. However, the application of HSV-tk is
blocked badly because of the lack of tumor-specific target-
ing capability; thus, the key to improve this type of ther-
apy is finding a way to improve tumor specificity [18,19].
Previous studies have indicated that LMP1 possesses the
ability to transactivate HIV-LTR through the NF-κB bind-
ing motifs. Chang's data showed that the HSV-tk gene
expressed from a NF-kappa B-binding motif-containing
promoter that is regulated by LMP1 could inhibit cell pro-
liferation in LMP1 positive cells such as C33A cell clones
and restrain the tumor growth in vivo[9]. In this study, the
effects of the pVLTR-tk, which expresses HSV-tk that is reg-
ulated by EBV-LMP1 via NF-κB was investigated by
employing different cell lines, including the CNE1, CNE1-
LMP1, HNE2-LMP1, and other EBV-related cancer cells.
The result showed that the pVTR-TK/GCV system had tox-
icity to the EBV-related cells and tumor. At the same time,
we also observed a significant bystander effect. In addi-
tion, ours results indicated that apoptosis is the main
mechanism involved in the death of LMP1 positive cells
upon their treatment with the pVLTR-tk/GCV system. In
Inhibition of nasopharyngeal carcinoma growth in athymic  nude mice with pVLTR-tk/GCV treatment Figure 6
Inhibition of nasopharyngeal carcinoma growth in 
athymic nude mice with pVLTR-tk/GCV treatment. 
Five mice per group were injected intratumorally every 24 
hours for 7 days with GCV (100 μmg/g avoirdupois). The 
cancer growth was monitored every 2 days using calipers.
pVLTR-tk/GCV enhance apoptosis in LMP1 positive cells Figure 5
pVLTR-tk/GCV enhance apoptosis in LMP1 positive 
cells. Cells were transfected with pVLTR-tk and treated 
with GCV. Cell apoptosis was measured by flow cytometry.Journal of Experimental & Clinical Cancer Research 2008, 27:42 http://www.jeccr.com/content/27/1/42
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conclusion, the combination of pVLTR-tk gene expression
and treatment with GCV could result in the capacity to kill
LMP1-expressing tumor cells effectively.
In vitro and in vivo experiments in the present study
revealed that EBV-LMP1 negative CNE1 cells also exhib-
ited a moderate killing effect after treatment with pVLTR-
tk/GCV. It will be important to investigate the toxic effects
of pVLTR-tk/GCV genes in normal tissues. However, this
new targeted strategy of the HSV-tk/GCV system may be
used as a gene therapy strategy for EBV-LMP1 positive can-
cers. Because LMP1 is expressed only in tumor cells, and
not in normal tissue cells, this therapeutic strategy could
enhance the targeting efficacy of the HSV-tk/GCV system.
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